MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing, announce that they had entered into a definitive agreement in which MacroGenics will sell its good manufacturing practice (GMP) drug substance manufacturing operations to Bora, subject to customary closing conditions. MacroGenics will receive $122.5 million upfront payment from Bora upon closing. The transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora.
Read the full article: MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2026/05/11/3292410/0/en/macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals.html